101 related articles for article (PubMed ID: 16406976)
1. Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
Catto JW; Abbod MF; Linkens DA; Hamdy FC
J Urol; 2006 Feb; 175(2):474-9. PubMed ID: 16406976
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
Catto JW; Linkens DA; Abbod MF; Chen M; Burton JL; Feeley KM; Hamdy FC
Clin Cancer Res; 2003 Sep; 9(11):4172-7. PubMed ID: 14519642
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
4. Artificial intelligence and bladder cancer arrays.
Wild PJ; Catto JW; Abbod MF; Linkens DA; Herr A; Pilarsky C; Wissmann C; Stoehr R; Denzinger S; Knuechel R; Hamdy FC; Hartmann A
Verh Dtsch Ges Pathol; 2007; 91():308-19. PubMed ID: 18314629
[TBL] [Abstract][Full Text] [Related]
5. Neural network analysis of clinicopathological and molecular markers in bladder cancer.
Qureshi KN; Naguib RN; Hamdy FC; Neal DE; Mellon JK
J Urol; 2000 Feb; 163(2):630-3. PubMed ID: 10647699
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of intelligent models for the prediction of bladder cancer progression.
Abbod MF; Linkens DA; Catto JW; Hamdy FC
Oncol Rep; 2006; 15 Spec no.():1019-22. PubMed ID: 16525693
[TBL] [Abstract][Full Text] [Related]
7. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis.
Bassi P; Sacco E; De Marco V; Aragona M; Volpe A
BJU Int; 2007 May; 99(5):1007-12. PubMed ID: 17437435
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
9. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
[TBL] [Abstract][Full Text] [Related]
10. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
[TBL] [Abstract][Full Text] [Related]
11. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
[TBL] [Abstract][Full Text] [Related]
12. Neuro-fuzzy system for prostate cancer diagnosis.
Benecchi L
Urology; 2006 Aug; 68(2):357-61. PubMed ID: 16904452
[TBL] [Abstract][Full Text] [Related]
13. Predicting survival after radical cystectomy for bladder cancer.
Margulis V; Lotan Y; Montorsi F; Shariat SF
BJU Int; 2008 Jul; 102(1):15-22. PubMed ID: 18325050
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence for predicting recurrence-free probability of non-invasive high-grade urothelial bladder cell carcinoma.
Cai T; Conti G; Nesi G; Lorenzini M; Mondaini N; Bartoletti R
Oncol Rep; 2007 Oct; 18(4):959-64. PubMed ID: 17786360
[TBL] [Abstract][Full Text] [Related]
15. Nomograms provide improved accuracy for predicting survival after radical cystectomy.
Shariat SF; Karakiewicz PI; Palapattu GS; Amiel GE; Lotan Y; Rogers CG; Vazina A; Bastian PJ; Gupta A; Sagalowsky AI; Schoenberg M; Lerner SP
Clin Cancer Res; 2006 Nov; 12(22):6663-76. PubMed ID: 17121885
[TBL] [Abstract][Full Text] [Related]
16. Nomograms for bladder cancer.
Shariat SF; Margulis V; Lotan Y; Montorsi F; Karakiewicz PI
Eur Urol; 2008 Jul; 54(1):41-53. PubMed ID: 18207314
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
19. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
